|国家预印本平台
首页|Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

来源:medRxiv_logomedRxiv
英文摘要

ABSTRACT BackgroundThe purpose of this study was to evaluate whether a bivalent COVID-19 vaccine protects against COVID-19. MethodsEmployees of Cleveland Clinic in employment when the bivalent COVID-19 vaccine first became available, were included. Cumulative incidence of COVID-19 over the following 26 weeks was examined. Protection provided by vaccination (analyzed as a time-dependent covariate) was evaluated using Cox proportional hazards regression, with change in dominant circulating lineages over time accounted for by time-dependent coefficients. The analysis was adjusted for the pandemic phase when the last prior COVID-19 episode occurred, and the number of prior vaccine doses. ResultsAmong 51017 employees, COVID-19 occurred in 4424 (8.7%) during the study. In multivariable analysis, the bivalent vaccinated state was associated with lower risk of COVID-19 during the BA.4/5 dominant (HR, .71; 95% C.I., .63-.79) and the BQ dominant (HR, .80; 95% C.I., .69-.94) phases, but decreased risk was not found during the XBB dominant phase (HR, .96; 95% C.I., .82-.1.12). Estimated vaccine effectiveness (VE) was 29% (95% C.I., 21%-37%), 20% (95% C.I., 6%-31%), and 4% (95% C.I., -12%-18%), during the BA.4/5, BQ, and XBB dominant phases, respectively. Risk of COVID-19 also increased with time since most recent prior COVID-19 episode and with the number of vaccine doses previously received. ConclusionsThe bivalent COVID-19 vaccine given to working-aged adults afforded modest protection overall against COVID-19 while the BA.4/5 lineages were the dominant circulating strains, afforded less protection when the BQ lineages were dominant, and effectiveness was not demonstrated when the XBB lineages were dominant. SummaryAmong 51017 working-aged Cleveland Clinic employees, the bivalent COVID-19 vaccine was 29% effective in preventing infection while the BA.4/5 lineages were dominant, and 20% effective while the BQ lineages were. Effectiveness was not demonstrated when the XBB lineages were dominant.

Nowacki Amy S.、Hagen Amanda、Gordon Steven M.、Burke Patrick C.、Shrestha Nabin K.、Simon James F.

Quantitative Health Sciences, Cleveland ClinicOccupational Health, Cleveland ClinicDepartments of Infectious Diseases, Cleveland ClinicInfection Prevention, Cleveland ClinicDepartments of Infectious Diseases, Cleveland ClinicEnterprise Business Intelligence, Cleveland Clinic

10.1101/2022.12.17.22283625

预防医学医学研究方法医药卫生理论

SARS-CoV-2COVID-19effectivenessvaccinesbivalent vaccine

Nowacki Amy S.,Hagen Amanda,Gordon Steven M.,Burke Patrick C.,Shrestha Nabin K.,Simon James F..Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine[EB/OL].(2025-03-28)[2025-08-02].https://www.medrxiv.org/content/10.1101/2022.12.17.22283625.点此复制

评论